Clorox Co (NYSE:CLX) saw a large growth in short interest in October. As of October 31st, there was short interest totalling 8,300,000 shares, a growth of 5.1% from the September 30th total of 7,900,000 shares. Approximately 6.6% of the company’s stock are short sold. Based on an average daily volume of 981,500 shares, the short-interest ratio is currently 8.5 days.
A number of equities research analysts have recently weighed in on CLX shares. Barclays set a $138.00 price target on Clorox and gave the stock a “sell” rating in a research note on Friday, November 1st. Cfra downgraded Clorox from a “hold” rating to a “sell” rating in a research note on Friday, November 1st. Deutsche Bank cut their price target on Clorox from $151.00 to $145.00 and set a “hold” rating for the company in a research note on Thursday, October 3rd. Royal Bank of Canada raised their price objective on Clorox to $161.00 and gave the company a “sector perform” rating in a research note on Friday, August 2nd. Finally, Zacks Investment Research raised Clorox from a “sell” rating to a “hold” rating and set a $175.00 price objective on the stock in a research note on Monday, July 29th. Five analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $152.00.
In other news, SVP Michael R. Costello sold 6,997 shares of the firm’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $162.56, for a total transaction of $1,137,432.32. Following the completion of the sale, the senior vice president now directly owns 29,016 shares of the company’s stock, valued at approximately $4,716,840.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Andrew J. Mowery sold 5,648 shares of the firm’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $146.29, for a total value of $826,245.92. Following the sale, the senior vice president now directly owns 15,920 shares of the company’s stock, valued at $2,328,936.80. The disclosure for this sale can be found here. Insiders have sold a total of 15,870 shares of company stock valued at $2,484,000 over the last ninety days. Company insiders own 1.14% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CLX. Marshall Wace North America L.P. acquired a new stake in shares of Clorox in the first quarter valued at about $65,000. Thomasville National Bank increased its position in Clorox by 9.2% during the second quarter. Thomasville National Bank now owns 3,570 shares of the company’s stock worth $547,000 after purchasing an additional 300 shares during the last quarter. Pensionfund DSM Netherlands acquired a new stake in Clorox during the second quarter worth about $2,373,000. Pensionfund Sabic acquired a new stake in Clorox during the second quarter worth about $1,608,000. Finally, Rockland Trust Co. increased its position in Clorox by 26.4% during the second quarter. Rockland Trust Co. now owns 5,489 shares of the company’s stock worth $840,000 after purchasing an additional 1,145 shares during the last quarter. 79.14% of the stock is currently owned by hedge funds and other institutional investors.
Shares of CLX stock opened at $145.74 on Tuesday. The stock’s 50 day simple moving average is $148.98 and its 200 day simple moving average is $153.91. The company has a debt-to-equity ratio of 4.69, a quick ratio of 0.52 and a current ratio of 0.87. Clorox has a twelve month low of $143.58 and a twelve month high of $167.70. The company has a market capitalization of $18.36 billion, a price-to-earnings ratio of 23.06, a PEG ratio of 4.68 and a beta of 0.38.
Clorox (NYSE:CLX) last issued its quarterly earnings data on Thursday, October 31st. The company reported $1.59 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.54 by $0.05. Clorox had a return on equity of 123.56% and a net margin of 13.20%. The business had revenue of $1.51 billion for the quarter, compared to the consensus estimate of $1.51 billion. During the same period last year, the business earned $1.62 EPS. The firm’s revenue was down 3.6% compared to the same quarter last year. On average, analysts forecast that Clorox will post 6.16 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Friday, November 15th. Shareholders of record on Wednesday, October 30th were issued a $1.06 dividend. This represents a $4.24 dividend on an annualized basis and a yield of 2.91%. The ex-dividend date of this dividend was Tuesday, October 29th. Clorox’s dividend payout ratio (DPR) is currently 67.09%.
Clorox Company Profile
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.
Read More: Hang Seng Index (HSI)
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.